Parkin (protein)
Parkin is a protein that in humans is encoded by the PARK2 gene. It is a member of the ubiquitin-protein ligase family, which plays a crucial role in the ubiquitin-proteasome system responsible for protein degradation. Parkin is involved in the regulation of various cellular processes, including mitophagy, the selective degradation of mitochondria by autophagy.
Function[edit | edit source]
Parkin functions as an E3 ubiquitin ligase, which facilitates the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific substrate proteins. This process tags the substrate proteins for degradation by the proteasome. Parkin is particularly important in maintaining mitochondrial quality control. It is recruited to damaged mitochondria, where it ubiquitinates various mitochondrial surface proteins, marking them for degradation and promoting the removal of dysfunctional mitochondria through mitophagy.
Clinical Significance[edit | edit source]
Mutations in the PARK2 gene are associated with autosomal recessive juvenile Parkinsonism (AR-JP), a form of Parkinson's disease (PD) that typically manifests at an early age. These mutations can lead to the loss of Parkin's E3 ligase activity, resulting in the accumulation of damaged mitochondria and neuronal cell death. Understanding the role of Parkin in mitochondrial maintenance has significant implications for developing therapeutic strategies for Parkinson's disease and other neurodegenerative disorders.
Structure[edit | edit source]
The Parkin protein contains several functional domains, including an ubiquitin-like domain (Ubl), a RING finger domain, and an in-between ring domain (IBR). These domains are essential for its E3 ligase activity and its interactions with other proteins involved in the ubiquitination process.
Research[edit | edit source]
Ongoing research is focused on elucidating the detailed mechanisms by which Parkin regulates mitophagy and how its dysfunction contributes to the pathogenesis of Parkinson's disease. Studies are also exploring potential therapeutic approaches to enhance Parkin activity or compensate for its loss in patients with PARK2 mutations.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD